Microvascular dysfunction and INOCA (Ischemia with Non-Obstructive Coronary Arteries) cause angina without the blockages a catheterization can see. EECP works at the small-vessel level, where the actual problem lives, to restore flow and reduce symptoms.
Non-obstructive coronary artery disease is angina without significant blockage on a catheterization, usually driven by dysfunction in the smallest vessels, the ones too small for stents to reach.
Small coronary arteries fail to dilate properly during stress. Blood flow is restricted at the capillary level, causing angina even when the larger arteries are open.
Ischemia with Non-Obstructive Coronary Arteries. The umbrella diagnosis when chest pain, abnormal stress testing, or biomarkers show ischemia, but the cath is clean.
Episodic spasm of the coronary arteries that mimics blockage during attacks. Often happens at rest, often missed on stress tests.
Standard angiography only shows obstruction in vessels larger than ~400 microns. Most CMD lives in vessels far smaller, invisible to the cath but very real to the patient.
EECP’s pneumatic counterpulsation creates increased shear stress along the entire endothelium, including the microvasculature that stents and bypass can’t address.
The diastolic augmentation EECP produces increases nitric oxide release across the small-vessel endothelium, the exact mechanism impaired in CMD.
By raising coronary perfusion pressure during diastole, EECP recruits and dilates the small arterioles that aren’t visible on standard angiography.
Improved endothelial tone reduces the inappropriate vasoconstriction that drives Prinzmetal’s-type chest pain, lowering attack frequency and severity.
Symptom relief commonly persists 1–3 years after a single 35-session course. The endothelial changes EECP induces are durable, not just acute.
CMD and INOCA are newer diagnoses in cardiology, and EECP research has tracked that growth. Here’s where the evidence stands today.
EECP appears uniquely suited to non-obstructive coronary syndromes because it acts on the endothelium and microvasculature, the structures these conditions actually involve, and the ones revascularization cannot reach.Adapted from current expert consensus on EECP & CMD
Standard of care for CMD/INOCA still emphasizes risk-factor modification and antianginals first. EECP is most appropriate when symptoms persist on optimal medical therapy, the same threshold that defines chronic angina coverage.
Standard angiography sees the larger coronary arteries. It can’t see the microvasculature, which is where roughly 40–50% of angina without obstruction actually originates. Your symptoms are real, they’re just from a layer the cath couldn’t visualize.
Medicare’s coverage criterion is chronic angina (CCS class III/IV) on optimal medical therapy, not the presence of obstruction. CMD and INOCA patients who meet that symptom threshold are typically eligible. Our team handles the prior-auth paperwork and confirms before treatment.
Exercise-based rehab also improves endothelial function, through your own effort. EECP produces a similar (and in some studies stronger) endothelial response without requiring you to exert through chest pain. The two are often complementary; EECP is especially useful when symptoms limit your ability to exercise effectively.
Most patients begin reporting reduced episode frequency around the 15–20 session mark. The full benefit shows up after the complete 35-session course. CMD responses tend to develop slightly more gradually than obstructive angina, persistence through the full course matters.
About 15–20% of patients in any cohort don’t experience meaningful symptom reduction. We screen carefully before starting to set realistic expectations, and we monitor response throughout. If you’re not responding at the midpoint, we’ll have a frank conversation about whether to continue.
No surgery talk. No commitment. Just answers from the team that has helped 50,000+ patients regain energy, walk further, and feel like themselves again.
